HIGHBuilt-inProduct / Revenue mix
70%
CSS segment
“10-K Item 1: 'The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies'”
IART · Concentration risk · 10-K extracted
Integra LifeSciences Holdings C (IART) concentration risks
Updated
The most significant concentration Integra LifeSciences Holdings C discloses is CSS segment at 70%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Integra LifeSciences Holdings C’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
limited number of suppliers
“10-K Item 1: 'certain components and raw materials are available only from one or a limited number of suppliers'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Integra LifeSciences' revenue is concentrated in a single business line: the CSS segment represents approximately 70% of total revenue, a structural feature of the company's current mix rather than a customer or counterparty dependency. On the supply side, the company discloses that certain components and raw materials are available only from one or a limited number of suppliers, a moderate-share exposure characterized as a dependency risk. These two exposures net out differently. The CSS concentration is baked into the business model — it reflects what Integra is today rather than a fragile reliance on an external party, so it would only move the verdict if that segment itself experienced a shock. The supplier exposure, by contrast, is the more idiosyncratic risk: a disruption at one of those limited-source suppliers could constrain production for the affected components regardless of underlying demand. The segment concentration carries the larger disclosed share of the two, while the supplier dependency is the one most likely to translate into an unexpected, single-source shock if it materializes.
For the engine’s reasoning on IART’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| IART● | Integra LifeSciences Holdings C | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.